Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification (PRO-145/III)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03693989
Recruitment Status : Completed
First Posted : October 3, 2018
Results First Posted : December 2, 2019
Last Update Posted : December 2, 2019
Sponsor:
Information provided by (Responsible Party):
Laboratorios Sophia S.A de C.V.

Brief Summary:

objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification.

Hypothesis:

The use of the ophthalmic emulsion PRO-145 is effective in decreasing the inflammatory response evaluated by means of cellularity in the anterior chamber, after phacoemulsification.

Methodology:

Phase III clinical trial, double-blind, controlled, parallel group, multicentre, randomized.

Number of patients:

178 subjects divided into 2 groups (89 subjects per group), who will provide an eye for the evaluation of efficacy.

Diagnosis and main inclusion criteria:

Diagnosis: Postoperative phacoemulsification and foldable intraocular lens placement in a bag.


Condition or disease Intervention/treatment Phase
Cataract Drug: Difluprednate 0.05% Drug: Prednefrin Phase 3

Detailed Description:

The study subjects will be recruited from various research centers in western and central Mexico.

Each research center has a monitoring plan specified according to the recruitment capabilities of the same, which must be at least once a month, where the queries of your data entered into the electronic case report report will be reported to the center. (e-CRF) for which it has as time limit the next monitoring visit to make the pertinent changes.

The report of adverse events will be made according to the standard operating procedure (PNO) where it specifies, according to Official Mexican Standard 220 (NOM 220), that the signs or symptoms of adverse events will be reported based on the Medical Dictionary. for Regulatory Activities, for which the sponsor has version 20.1 in Spanish. For serious adverse events (SAEs) will be reported in accordance with the standardized operation procedure of pharmacovigilance of the sponsor, which adheres to the guidelines of NOM 220 and international regulations, these will be reported in the regulatory framework to the regulatory entity within a period of time no more than 7 days.

The study is registered in the National Registry of Clinical Trials (RNEC), entity equivalent to Clinical Trials in Mexico.

The quality assurance plan is carried out by the sponsor through the Quality Assurance agent in Clinical Research, whose function is to conduct inspections and audits of the research sites to document and generate reports of deviations from the protocol. In addition to the visits of the monitoring plan, the reliability of the data is guaranteed.

To verify the integrity, veracity and reliability of the data entered into the e-CRF, the monitors of each center will check the information uploaded to the portal with that reported in the source document of the principal investigator (PI), such as clinical notes, clinical history and documents. and formats attached to the research protocol, physical case report format, as well as those provided by the sponsor to the PI (subject's diary and quality and satisfaction survey).

The e-CRF used for this clinical study is provided by an internationally certified provider with the highest quality standards, protection of information under current regulations and confidentiality guarantee. The information that the PIs enter into the e-CRF is collated and verified by the clinical monitors and by the service provider's personnel, later reviewed and approved by the medical ophthalmologist researcher and by the Clinical Security Pharmacologist, who authorize the monitored data of clinical information and safety of the study molecule, respectively.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 178 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: double-blind, controlled, parallel group, multicentre, randomized
Masking: Double (Participant, Investigator)
Masking Description:

Blinding and masking The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner in the case of a partial and final analysis.

The masking will be carried out using boxes in the identical primary packaging in the two groups and re-labeling the bottles of both interventions.

Blinding for the research subject and the researcher will be done by replacing the commercial labels in the case of the comparator in the bottles and the use of identical labels that contain the assignment number.

Primary Purpose: Treatment
Official Title: Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for the Management of Inflammation and Pain After Phacoemulsification Compared to Prednisolone Acetate 1%.
Actual Study Start Date : October 4, 2018
Actual Primary Completion Date : August 7, 2019
Actual Study Completion Date : October 22, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PRO-145.
Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
Drug: Difluprednate 0.05%
Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
Other Name: PRO-145

Active Comparator: Prednefrin
Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.
Drug: Prednefrin

1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.

- Route of administration: topical ophthalmic

Other Name: Difluprednate




Primary Outcome Measures :
  1. Visual Ability (VA) [ Time Frame: day 28 at the final visit ]
    The VA will be evaluated basally, without refractive correction with the Snellen chart. Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The result of the Snellen fraction will be transformed to its decimal equivalent in LogMAR, ex. 20/20= 1.0, 20/25=0.8, 20/40= 0.5, 20/200= 1.0, etc. The subjects will be averaged by group.

  2. Adverse Events [ Time Frame: day 28 at the final visit ]

    The evaluation of adverse events requires a questioning conducted by the principal investigator and the appropriate exploratory techniques for its detection.

    the number of cases with adverse events will be reported per study arm



Secondary Outcome Measures :
  1. Cellularity in the Anterior Chamber [ Time Frame: day 28 at the final visit ]

    unit: degrees, Direct observation (Biomicroscopy).

    Scale for anterior chamber cellularity. Grade/Number of cells

    Grade / Number of cells

    0 Any

    ½ + 1-5

    1. + 6-15
    2. + 16-25
    3. + 26-60
    4. + More than 60

    the cellularity will be measured according to the scale that is added next, considering as normal the degree 0, and abnormal any other degree.


  2. Clinical Corneal Edema [ Time Frame: day 28 at the final visit ]

    The evaluation of clinical edema will be evaluated by the Efron scale, which is a series of factorial sections of the cornea, including features such as grooves and folds. The Efron scale has a strong correlation with variations in intensity. The number will be reported according to the rating awarded.

    Efron Scale: 0 Normal, 1 very slight, 2 mild, 3 moderate and 4 severe.


  3. Flare [ Time Frame: day 28 at the final visit ]

    In the presence of intraocular inflammation, the increased permeability of the non-pigmented layer of the ciliary epithelium, the posterior epithelium of the iris and the vascular endothelium of the iris results in the accumulation of cells and proteins (visible to the examiner as flare) in the anterior chamber. Using a light beam of 0.2mm X 0.2mm directed obliquely to the anterior chamber with a forward inclination of the light source (slit lamp tower) the degree of flare and cellularity will be determined according to the group of work of standardization for the nomenclature of uveitis.

    Flare scale

    0 There is no flare

    1. + Mild
    2. + Moderate (iris and crystalline clearly visible)
    3. + Marking (iris and crystalline slightly blurred)
    4. + More than 60 (fibrin)

  4. Central Thickness of the Retina [ Time Frame: day 28 at the final visit ]
    By means of optical coherence tomography (OCT) the Retinal central thickness (GCR) will be measured. OCT is a noninvasive imaging test that uses light waves to take photographs of the cross section of the retina (the light-sensitive tissue that lines the back of the eye).With a OCT, each of the characteristic layers of the retina can be observed, allowing mapping and measuring its thickness a micrometer result will be obtained and the analysis will be carried out between groups.

  5. Conjunctival Hyperemia [ Time Frame: day 28 at the final visit ]

    Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance secondary to the vasodilation of the conjunctival vessels of variable intensity, we will use the Efron scale for conjunctival hyperemia.

    0 normal

    1. very slight
    2. mild
    3. moderate
    4. severe

  6. Intraocular Pressure [ Time Frame: day 28 at the final visit ]
    Tonometry is the objective measure of Intraocular pressure, based primarily on the force required to flatten the cornea, or the degree of corneal indentation produced by a fixed force. Goldman's tonometry is based on the Imbert-Fick principle. the result will be expressed in millimeters of mercury and the comparison between groups will be carried out

  7. Symptomatology Post Instillation [ Time Frame: day 28 at the final visit ]

    The subject will be questioned if after applying the medication he felt burning, pruritus, a foreign body sensation and blurred vision.

    Presence or absence: it will be marked as present (1) or absent (0) for each of the symptoms questioned




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent.
  • Age ≥ 18 years.
  • Both sexes.
  • Postoperative cataract surgery by phacoemulsification. o That they have met the criteria for phacoemulsification and a classification of the lens opacity classification system (LOCS) III cataract of Opalescence of the nucleus (NO) ≥2 and Kernel color (NC) ≥2.

Exclusion Criteria:

  • Pregnant women, lactating or planning to get pregnant.
  • Women of reproductive age and who do not have a hormonal contraceptive method, intrauterine device or bilateral tubal obstruction.
  • Participation in another clinical research study ≤ 30 days before the baseline visit.
  • Have previously participated in this same study with the contralateral eye.
  • That they can not comply with their attendance at appointments or with all the requirements of the protocol.

Medical and therapeutic criteria.

  • Surgery in both eyes in the same surgical shift.
  • Time> 24 hours after having surgery.
  • Intraocular lens placement outside the bag.
  • Presentation of rupture of the posterior capsule, with or without the presence of vitreous.
  • Carrying out an iridectomy, or lesion of the pupillary sphincter during phacoemulsification surgery.
  • Scheduled for surgical intervention in the contralateral eye during the study period.
  • History of glaucoma or ocular hypertension.
  • History of increased Intraocular pressure (IOP) with the use of steroids.
  • Intraocular pressure (IOP) ≥24.
  • History of uveitis.
  • Presence of corneal abrasion or corneal ulceration in the study eye.
  • Use of steroids or topical non steroidal anti inflammatory drugs, 24 hours prior to surgery and until the start of instillation of investigational drugs.
  • Use of anticoagulants, systemic steroids or immunomodulators in the last two weeks
  • Periocular injection of any steroid in the study eye 4 weeks before the start of the instillation of the investigational drugs.
  • Use of storage steroids 2 months prior to the start of instillation of investigational drugs.
  • Presence or suspicion of keratitis and / or viral, bacterial or fungal conjunctivitis.
  • Presence or suspicion of endophthalmitis.
  • Presence or suspicion of toxic syndrome of the anterior segment.
  • Severe corneal edema that does not allow assessment of the anterior chamber
  • Macular diseases.
  • Diabetes Mellitus with glycosylated hemoglobin (A1C) ≥ 6.5% (48 mmol / mol) or fasting glucose (no caloric intake by ≥ 8 hours) of ≥ 126 mg / dL (7.0 mmol / L).
  • Any disease or condition that requires the use of topical or systemic nonsteroidal anti-inflammatories (NSAIDs) during the time of intervention.
  • Any disease or condition that requires the use of steroids other than topical ophthalmic application.
  • Subjects with a single eye.
  • Any condition or disease that at the discretion of the principal investigator (IP) does not make the subject suitable for the study.
  • Known hypersensitivity to the components of the products under investigation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03693989


Locations
Layout table for location information
Mexico
Catarata y Glaucoma de Occidente
Guadalajara, Jalisco, Mexico, 44160
Novam y Vita
Guadalajara, Jalisco, Mexico, 44620
Vision Cirugia Ambulatoria
Monterrey, Nuevo Leon, Mexico, 64710
Hospital de la luz
Ciudad de Mexico, Mexico, 06030
Fundación de asistencia privada Conde de Valenciana
Ciudad de Mexico, Mexico, 06800
Sponsors and Collaborators
Laboratorios Sophia S.A de C.V.
Investigators
Layout table for investigator information
Study Director: Leopoldo Baiza Durán, MD Laboratorios Sophia S.A de C.V.
  Study Documents (Full-Text)

Documents provided by Laboratorios Sophia S.A de C.V.:

Layout table for additonal information
Responsible Party: Laboratorios Sophia S.A de C.V.
ClinicalTrials.gov Identifier: NCT03693989    
Other Study ID Numbers: SOPH145-0716 / III
First Posted: October 3, 2018    Key Record Dates
Results First Posted: December 2, 2019
Last Update Posted: December 2, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Laboratorios Sophia S.A de C.V.:
corticosteroid
anti-inflammatory steroid
phacoemulsification
Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Inflammation
Pathologic Processes
Lens Diseases
Eye Diseases
Prednisolone
Prednisolone acetate
Fluprednisolone
Difluprednate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents